This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Highly active antiretroviral treatment (HAART) results in impressive improvement in human immunodeficiency virus-1 (HIV)-related disease. However, drug treatment may increase the risk of heart disease. Developing high blood cholesterol and abnormal blood vessel function may cause this risk. By studying a variety of subjects with HIV infection, both on HAART and not, we propose to establish the variables that are most important at causing abnormal blood vessel function at various stages of treatment.The primary objective is to assess whether the endothelial dysfunction that has been reported during prolonged treatment is primarily the result of the high blood cholesterol and insulin resistance that is associated with the development of lipodystophy. The study will be observational in nature and will not specify what HIV treatment subjects will receive. Cross-sectional and longitudinal components are included. Drug-naive subjects who are enrolled into the cross-sectional study may also be eligible for the longitudinal evaluations. The longitudinal study will primarily be exploratory in nature.
Showing the most recent 10 out of 767 publications